Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
When it comes to Spondyloarthritis we have numerous disease activity measures and much debate regarding best practices. When it comes to determining which to use in clinic, discrepancies occur. Do our activity measures truly represent disease? Are there some measures best suited to different populations? Does BASDAI work for women?
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do list. In the least, you should be familiar with the names and objectives of some of these studies as they will be discussed and mentioned throughout the meeting.
Abbvie
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com and looks forward to highlight sessions in the next few days at ACR Convergence 2022.
sheila RHEUMarampa
3 years 1 month ago
Dr. Coldiron (thru case examples) shares how the MSF works in providing medical care to pts in areas of conflict or crisis & how #climate change has also impacted health, including #Mentalhealth
#ACR22 @RheumNow @rheumarhyme https://t.co/gFuX4sL0WA
TheDaoIndex KDAO2011
3 years 1 month ago
50 yo hispanic male +MDA5 Ab w/ synovitis, skin lesions, neg ANA, normal CK, aldolase, +MDA5 Ab, Skin biopsy show changes c/w dermatomyositis. Failed MTX/MMF, no insurance. What is MDA5's role? Does race play a factor in Rx response? What is your next step? @rheumnow #ACR22 https://t.co/tGy2BH6y45
TheDaoIndex KDAO2011
3 years 1 month ago
Dr. R Puligari:
55 yo female w/arthritis, rash, DOE, fever, weight loss, CT abnormal +MDA5 dermatomyositis: Rx RTX, IV steroids, CYP, TAC and Ofev. Disease progressed; IVIG,steroids, PLEX added w/benefits. 6 months later had CMV retinitis. What to do next? #ACR22 @rheumnow https://t.co/A1m8HMtCob
Janet Pope Janetbirdope
3 years 1 month ago
#ClinicalPearl #Methotrexate is recommended for Rx in all EXCEPT…#ACR22 @RheumNow
TheDaoIndex KDAO2011
3 years 1 month ago
Dr. M Tikly share #rheum challenges & solutions in South Africa:
👉⬆️training to gen. practitioners & nurses, 👉estab outreach clinics
👉lobby local government/political groups
👉use of off-label drugs
👉engage pharma: free meds/clinical trials #ACR22 #GlobalHealth @rheumnow https://t.co/BX2qXk1usN
sheila RHEUMarampa
3 years 1 month ago
Dr. Tikly discusses the solutions to drug access challenges in South Africa in both state and private sectors 👇
🔸Off label use, buyouts, price⬇️, advocacy...
Highly relatable because these are similar challenges we face in the PH @rheumarhyme @doktora_ging
#ACR22 @rheumnow https://t.co/ajshylgtIE
David Liew drdavidliew
3 years 1 month ago
Finally we're starting to get therapies for polymyalgia rheumatica!
The best of PMR therapeutics coming up at #ACR22 (and catch it all @RheumNow): https://t.co/lUPICA3Mim
Dr. John Cush RheumNow
3 years 1 month ago
#ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs
New research being presented at #ACR22, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with combo DMARDSs.
https://t.co/qmfnEvDedA https://t.co/VhkYlZJG3s
Dr. John Cush RheumNow
3 years 1 month ago
Update: axSpA Recommendations
https://t.co/KaBb11WLQD https://t.co/8kIaa0WuvM
Dr. John Cush RheumNow
3 years 1 month ago
Study of 78 824 adults shows Prevalence of Cannabis use was significantly higher during the pandemic vs before the pandemic in states where it is legalized (but not increase in nonlegal states) esp in adults 18 to 29 and 30 to 54 years https://t.co/ZZzCl7dstj https://t.co/qbQLPhI6I8
Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the marketplace for RA treatments is becoming ever more crowded, there are still unmet needs.
Poster Hall